Resolution of cystic fibrosis-related diabetes with ivacaftor therapy

American Journal of Respiratory and Critical Care Medicine

Volumn 190, Issue 5, 2014, Pages 590-591

  Hayes, Don ^a   McCoy, Karen S ^a   Sheikh, Shahid I ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN GLARGINE; IVACAFTOR; AMINOPHENOL DERIVATIVE; ANTIDIABETIC AGENT; N-(2,4-DI-TERT-BUTYL-5-HYDROXYPHENYL)-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXAMIDE; QUINOLONE DERIVATIVE;

ADULT; CASE REPORT; CYSTIC FIBROSIS; CYSTIC FIBROSIS RELATED DIABETES; DIABETES MELLITUS; DRUG DOSE REDUCTION; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; LETTER; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; SPIROMETRY;

ADULT; AMINOPHENOLS; CYSTIC FIBROSIS; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; QUINOLONES;

EID: 84908147590     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201405-0882LE     Document Type: Letter

References (4)

1. Kelly A, Moran A. Update on cystic fibrosis-related diabetes. J Cyst Fibros 2013;12:318-331.
2. Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care 2009;32:1626-1631.
3. Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010;363:1991-2003.
4. Bellin MD, Laguna T, Leschyshyn J, Regelmann W, Dunitz J, Billings J, Moran A. Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study. Pediatr Diabetes 2013;14:417-421.